<< Back to News

MWi CEO Program featuring Kevin Conroy, President, CEO & Chairman, Exact Sciences

Exact Sciences is a “Power of 3” company, having three women board members and seven women executives. Mr. Conroy was featured in MWi’s 2019 research report.

Special Guest: Kevin T. Conroy, President, CEO & Chairman, Exact Sciences

Kevin shared his leadership journey and philosophy, what he looks for when selecting Board members, what he believes will move the gender parity needle, suggestions for women looking to secure a Board position and key executive roles, and more.

Kevin Conroy joined Exact Sciences in 2009 as CEO and president. Under his leadership, Kevin transformed Exact Sciences into one of the world’s premier cancer diagnostics companies with more than 4,500 employees under his leadership. He led Exact Sciences through the development, clinical trial, regulatory approval, and commercialization of its noninvasive colorectal cancer screening test, Cologuard®. This culminated with Cologuard becoming the first medical device or diagnostic to receive simultaneous FDA approval and national Medicare coverage. Since 2014, millions of Americans have used Cologuard to screen for colorectal cancer, the second leading cause of cancer death in the United States.

Mr. Conroy currently serves as a director of Epizyme, Inc. and Adaptive Biotechnology Corporation.

Link to recording:.  Kevin Conroy 3.3.21

A few of the topics Kevin addressed:

  • Business Overview: Exact Sciences
  • Market Trends and Factors
  • Leadership and Personal Philosophies
  • Women on Boards: Why that matters?
  • What will move the gender parity needle for all of us in the world of commerce?
  • How to be an effective Board member?
  • What do you look for when selecting Board members?
  • What do you enjoy about Board members?
  • Advice for those who are not only looking into Board positions, but also key Executive roles

About Exact Sciences

A leading provider of cancer screening and diagnostic tests, Exact Sciences relentlessly pursues smarter solutions providing the clarity to take life-changing action, earlier. Building on the success of Cologuard and Oncotype DX, Exact Sciences is investing in its product pipeline to take on some of the deadliest cancers and improve patient care. Exact Sciences unites visionary collaborators to help advance the fight against cancer. For more information, please visit the company’s website at www.exactsciences.com, follow Exact Sciences on Twitter @ExactSciences, or find Exact Sciences on Facebook.

Stay Informed

Sign up to receive email news and information from MWi.